Bell Potter slaps buy rating on this profitable, dividend-paying ASX cannabis share

This cannabis share is smoking the market on Monday…

The Cronos Australia Ltd (ASX: CAU) share price was a strong performer on Monday.

The medicinal cannabis company's shares ended the day 15% higher at 55 cents.

At one stage, the Cronos Australia share price even reached a record high of 58 cents.

two men in formal business clothing closely inspect a bud from a cannabis crop.

Image source: Getty Images

Why did the Cronos Australia share price fire up?

Investors have been scrambling to buy the company's shares over the last two trading sessions thanks to a bullish broker note out of Bell Potter.

According to the note, the broker has initiated coverage on the company with a buy rating and 60 cents price target.

Based on the current Cronos Australia share price, this implies further potential upside of 9.1% for investors.

What did the broker say?

Bell Potter likes the company due to its leadership position in medicinal cannabis distribution. It explained:

Cronos Australia is a medicinal cannabis company that is the market leader in distribution to pharmacies and provides patient consulting services through its clinic business. The key driver for the impressive growth in the past 24 months has been the CanView platform which provides the widest range of medicinal cannabis products compared to competitors (Anspec, Health House).

The current system provides access to patients, doctors and pharmacists. The transition to CanView 2.0 streamlines the consultation and prescription process.

In addition, the broker highlights that Cronos Australia is a profitable, dividend-paying cannabis share. The only one of its kind in Australia. Furthermore, it feels its valuation is fair and its growth outlook is strong. The broker concludes:

We initiate coverage on Cronos with a Buy recommendation. We expect the momentum observed in FY22 to continue into FY23 and translate into strong revenue and earnings growth. Cronos is currently the only profitable dividend paying medicinal cannabis company on the ASX and the valuation does not appear demanding relative to the expected growth.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A woman holds her finger to the side of her lips in contemplation as she looks upwards to an array of graphic images of light bulbs above her head, one of which is on and glowing.
Broker Notes

CSL, Westpac, BHP shares: Buy, hold, or sell?

Find out what the experts tip for these ASX 200 giants.

Read more »

Young successful engineer, with blueprints, notepad, and digital tablet, observing the project implementation on construction site and in mine.
Broker Notes

Could this ASX uranium developer more than double in value?

This company's African projects are shaping up well.

Read more »

Two work colleagues looking at a laptop and discussing something.
Broker Notes

Buy, hold, sell: Wildcat Resources, Ramsay Health Care, CBA shares

The market is down on Tuesday as experts reveal insights into these three companies.

Read more »

Excited couple celebrating success while looking at smartphone.
Broker Notes

2 ASX 300 shares tipped by brokers to return 16% to 38%

These shares could deliver market-beating returns according to analysts.

Read more »

Woman and man at work looking at data on a tablet at work.
Broker Notes

Buy, hold, sell: Fortescue, Guzman Y Gomez, and Megaport shares

Here's what Morgans is saying about these popular shares.

Read more »

Female scientist working in a laboratory.
Broker Notes

Buy, hold, sell: Mesoblast, Dicker Data, ASX shares

The drug maker is a standout among these companies.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

UBS' top nine ASX large-cap stock picks

Check out the price targets on these major shares.

Read more »

A woman in a red dress holding up a red graph.
Broker Notes

Up more than 1000% over a year, how much more upside does this ASX mining stock have?

This tin project developer has been kicking goals.

Read more »